Zobrazeno 1 - 7
of 7
pro vyhledávání: '"R M, Major"'
Autor:
A. McBurney, A. J. Peard, R Novellini, B. A. John, J D Holding, M P Ferrari, K Fitzpatrick, R Anacardio, S J Wright, R M Major, Ian Midgley
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 36(5)
The pharmacokinetics and metabolism of reparixin (formerly repertaxin), a potent and specific inhibitor of the chemokine CXCL8, were investigated in rats and dogs after intravenous administration of [14C]-reparixin L-lysine salt. Protein binding of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e9a0907952081c7a55f6b1a88c47c0
https://pubmed.ncbi.nlm.nih.gov/16854780
https://pubmed.ncbi.nlm.nih.gov/16854780
Publikováno v:
New Zealand Veterinary Journal. 27:58-61
The growth of a New Zealand strain of M. ovipneumoniae in broth culture at 37°C was examined. In these conditions, the organism had a minimum division time of 1.7 hr and attained a maximum titre of about 2×109 CFU/ml. Growth produced sufficient tur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d02b50be045cade37877ff07756b858
https://doi.org/10.1080/00480169.1979.34600
https://doi.org/10.1080/00480169.1979.34600
Autor:
C S R M Major Goldingham
Publikováno v:
Royal United Services Institution. Journal. 97:212-222
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89ef81cb95a3acc1128058afacc6e842
https://doi.org/10.1080/03071845209428813
https://doi.org/10.1080/03071845209428813
Autor:
S G, Wood, B A, John, L F, Chasseaud, R M, Major, M E, Forrest, R, Bonn, A, Darragh, R F, Lambe
Publikováno v:
Arzneimittel-Forschung. 34(9)
Single oral doses of 20 mg of the carbon-14 labelled form of the antianginal drug isosorbide 5-mononitrate (5-ISMN, Elantan) were essentially completely absorbed and excreted fairly rapidly in the urine. Means of 24, 52, 78, 93 and 96% dose were excr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3c184d93784bdedcd4468a60f7d20f50
https://pubmed.ncbi.nlm.nih.gov/6542370
https://pubmed.ncbi.nlm.nih.gov/6542370
Publikováno v:
Arzneimittel-Forschung. 28(8)
Plasma concentrations of isosorbide dinitrate have been measured after administration of increasing doses in the range 20--100 mg as sustained-release tablets (Isoket retard) containing 20 mg to human subjects. Means of peak concentrations of 4.2 ng/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5bc96a1714af997dfc31f078583f2942
https://pubmed.ncbi.nlm.nih.gov/582411
https://pubmed.ncbi.nlm.nih.gov/582411
Publikováno v:
Arzneimittel-Forschung. 34(11)
The relative bioavailability of isosorbide-5-mononitrate (IS-5-MN) has been determined after a 3-day period of dosing with 20 mg in standard-release reference tablets and sustained-release capsules at 12-h intervals, 40 mg in sustained-release capsul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::477faadd3fec4b143136a4c62d3a7e4f
https://pubmed.ncbi.nlm.nih.gov/6543135
https://pubmed.ncbi.nlm.nih.gov/6543135
Publikováno v:
Arzneimittel-Forschung. 33(9)
To study the influence of various in vitro release rates and of coadministration with food on bioavailability of isosorbide dinitrate (ISDN; isoket retard 40) and its mononitrate metabolites from sustained-release formulations the pharmacokinetics of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::668e7b368083a27549e92278c6d2468b
https://pubmed.ncbi.nlm.nih.gov/6685511
https://pubmed.ncbi.nlm.nih.gov/6685511